This is an investigator- and participant-blind, randomized, placebo-controlled, parallel-group, Phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of orally administered RO7795081 in otherwise healthy Chinese adult participants with obesity or overweight.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence, Severity, and Causal Relationship to Treatment of Adverse Events
Timeframe: Baseline to Safety Follow-Up (26 weeks)
Incidence of Abnormal Clinical Laboratory Test Findings
Timeframe: Baseline to Safety Follow-Up (26 weeks)
Incidence of Abnormal Vital Signs
Timeframe: Baseline to Safety Follow-Up (26 weeks)
Incidence of Abnormal Electrocardiogram (ECG) Results
Timeframe: Baseline to Safety Follow-Up (26 weeks)
Incidence of Abnormal Psychiatry Parameters
Timeframe: Baseline to Safety Follow-Up (26 weeks)
Reference Study ID Number: YP46260 https://forpatients.roche.com/